Effectiveness of Various Maintenance Therapy in Ovarian Cancer A Scoping Review

Mada Ilham Bawono, Belinda Mufidah

Sari


ABSTRACT

 

Ovarian cancer is highly lethal with a lifetime risk of up to 1.1%. Despite advances in treatment like cytoreductive surgery and chemotherapy, high recurrence rates challenge disease management. Maintenance therapy is crucial for extending progression-free survival (PFS) and delaying recurrence. This study aims to evaluate the effectiveness of various maintenance therapies published in the last 10 years, focusing on PARP inhibitors, angiogenesis inhibitors, monoclonal antibodies, and combination therapies. A scoping review was conducted following the PRISMA ScR Protocol. The search was conducted in PubMed, ScienceDirect, and Springer databases. After removing duplicates and applying inclusion and exclusion criteria, 208 articles were screened and 22 articles were selected for final review and critically appraised using the Cochrane RoB 2 tool. This review found that maintenance treatment with PARP inhibitors (e.g., olaparib, niraparib, rucaparib) showed significant improvements in PFS, especially in patients with BRCA mutations and homologous recombination deficiency (HRD). Combination therapies, such as olaparib with bevacizumab, also enhanced PFS. Angiogenesis inhibitors like pazopanib showed variable effectiveness, while monoclonal antibodies like gatipotuzumab had limited success. The combination of pegylated liposomal doxorubicin (PLD) with carboplatin showed potential in improving PFS. These findings highlight the effectiveness of personalized maintenance therapies in extending PFS in ovarian cancer patients.

 

Keywords: Ovarian Cancer, Maintenance Therapy


Referensi


Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S., Bannon, F., Ahn, J. V, Johnson, C. J., Bonaventure, A., Marcos-Gragera, R., Stiller, C., Azevedo e Silva, G., Chen, W.-Q., Ogunbiyi, O. J., Rachet, B., Soeberg, M. J., You, H., Matsuda, T., … Coleman, M. P. (2015). Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). The Lancet, 385(9972), 977–1010. https://doi.org/10.1016/S0140-6736(14)62038-9

Banerjee, S., Moore, K. N., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., Gourley, C., Oza, A., González-Martín, A., Aghajanian, C., Bradley, W. H., Holmes, E., Lowe, E. S., & DiSilvestro, P. (2021). Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 22(12), 1721–1731. https://doi.org/10.1016/S1470-2045(21)00531-3

Burke, W., Barkley, J., Barrows, E., Brooks, R., Gecsi, K., Huber-Keener, K., Jeudy, M., Mei, S., O’Hara, J. S., & Chelmow, D. (2023). Executive Summary of the Ovarian Cancer Evidence Review Conference. Obstetrics & Gynecology, 142(1), 179–195. https://doi.org/10.1097/AOG.0000000000005211

du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M.-A., Kim, J.-H., … Harter, P. (2014). Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. Journal of Clinical Oncology, 32(30), 3374–3382. https://doi.org/10.1200/JCO.2014.55.7348

Fujiwara, K., Fujiwara, H., Yoshida, H., Satoh, T., Yonemori, K., Nagao, S., Matsumoto, T., Kobayashi, H., Bourgeois, H., Harter, P., Mosconi, A. M., Vazquez, I. P., Reinthaller, A., Fujita, T., Rowe, P., Pujade-Lauraine, E., & Ray-Coquard, I. (2021). Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. Journal of Gynecologic Oncology, 32(5). https://doi.org/10.3802/jgo.2021.32.e82

González-Martín, A., Pothuri, B., Vergote, I., Graybill, W., Lorusso, D., McCormick, C. C., Freyer, G., Backes, F., Heitz, F., Redondo, A., Moore, R. G., Vulsteke, C., O’Cearbhaill, R. E., Malinowska, I. A., Shtessel, L., Compton, N., Mirza, M. R., & Monk, B. J. (2023). Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. European Journal of Cancer, 189, 112908. https://doi.org/10.1016/j.ejca.2023.04.024

Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., Dobbs, S., Essapen, S., Twigg, J., Herod, J., McCluggage, G., Parmar, M., & Swart, A.-M. (2015). Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet, 386(9990), 249–257. https://doi.org/10.1016/S0140-6736(14)62223-6

Kim, J.-W., Mahner, S., Wu, L.-Y., Shoji, T., Kim, B.-G., Zhu, J.-Q., Takano, T., Park, S.-Y., Kong, B.-H., Wu, Q., Wang, K.-L., Ngan, H. Y., Liu, J.-H., Wei, L.-H., Mitrica, I., Zhang, P., Crescenzo, R., Wang, Q., Cox, C. J., … du Bois, A. (2018). Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. International Journal of Gynecologic Cancer, 28(1), 2–10. https://doi.org/10.1097/IGC.0000000000000602

Lai, C.-H., Vallikad, E., Lin, H., Yang, L.-Y., Jung, S.-M., Liu, H.-E., Ou, Y.-C., Chou, H.-H., Lin, C.-T., Huang, H.-J., Huang, K.-G., Qiu, J., Hung, Y.-C., Wu, T.-I., Chang, W.-Y., Tan, K.-T., Lin, C.-Y., Chao, A., & Chang, C.-J. (2020). Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group. Journal of Gynecologic Oncology, 31(1). https://doi.org/10.3802/jgo.2020.31.e5

Ledermann, J. A., Zurawski, B., Raspagliesi, F., De Giorgi, U., Arranz Arija, J., Romeo Marin, M., Lisyanskaya, A., Póka, R. L., Markowska, J., Cebotaru, C., Casado Herraez, A., Colombo, N., Kutarska, E., Hall, M., Jacobs, A., Ahrens-Fath, I., Baumeister, H., Zurlo, A., & Sehouli, J. (2022). Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open, 7(1), 100311. https://doi.org/10.1016/j.esmoop.2021.100311

Li, N., Zhang, Y., Wang, J., Zhu, J., Wang, L., Wu, X., Yao, D., Wu, Q., Liu, J., Tang, J., Yin, R., Lou, G., An, R., Zhang, G., Xia, X., Li, Q., Zhu, Y., Zheng, H., Yang, X., … Wu, L. (2022). Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. Journal of Clinical Oncology, 40(22), 2436–2446. https://doi.org/10.1200/JCO.21.01511

Li, N., Zhu, J., Yin, R., Wang, J., Pan, L., Kong, B., Zheng, H., Liu, J., Wu, X., Wang, L., Huang, Y., Wang, K., Zou, D., Zhao, H., Wang, C., Lu, W., Lin, A., Lou, G., Li, G., … Wu, L. (2023). Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer. JAMA Oncology, 9(9), 1230. https://doi.org/10.1001/jamaoncol.2023.2283

Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., Ben-Baruch, N. E., Marth, C., Mądry, R., Christensen, R. D., Berek, J. S., Dørum, A., Tinker, A. V., du Bois, A., González-Martín, A., … Matulonis, U. A. (2016). Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. New England Journal of Medicine, 375(22), 2154–2164. https://doi.org/10.1056/NEJMoa1611310

Mizuno, M., Ito, K., Nakai, H., Kato, H., Kamiura, S., Ushijima, K., Nagao, S., Takano, H., Okadome, M., Takekuma, M., Tokunaga, H., Nagase, S., Aoki, D., Coleman, R. L., Nishimura, Y., Ratajczak, C. K., Hashiba, H., Xiong, H., Katsumata, N., … Okamoto, A. (2023). Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. International Journal of Clinical Oncology, 28(1), 163–174. https://doi.org/10.1007/s10147-022-02258-x

Nag, S., Aggarwal, S., Rauthan, A., & Warrier, N. (2022). Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review. Journal of Ovarian Research, 15(1), 88. https://doi.org/10.1186/s13048-022-01020-1

Phung, M. T., Pearce, C. L., Meza, R., & Jeon, J. (2023). Trends of Ovarian Cancer Incidence by Histotype and Race/Ethnicity in the United States 1992–2019. Cancer Research Communications, 3(1), 1–8. https://doi.org/10.1158/2767-9764.CRC-22-0410

Poveda, A., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M., Baldoni, A., Park-Simon, T.-W., Tamura, K., Sonke, G. S., Lisyanskaya, A., Kim, J.-H., Filho, E. A., Milenkova, T., Lowe, E. S., … Vergote, I. (2021). Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 22(5), 620–631. https://doi.org/10.1016/S1470-2045(21)00073-5

Wu, L., Zhu, J., Yin, R., Wu, X., Lou, G., Wang, J., Gao, Y., Kong, B., Lu, X., Zhou, Q., Wang, Y., Chen, Y., Lu, W., Li, W., Cheng, Y., Liu, J., Ma, X., & Zhang, J. (2021). Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecologic Oncology, 160(1), 175–181. https://doi.org/10.1016/j.ygyno.2020.10.005

Wu, X. H., Zhu, J. Q., Yin, R. T., Yang, J. X., Liu, J. H., Wang, J., Wu, L. Y., Liu, Z. L., Gao, Y. N., Wang, D. B., Lou, G., Yang, H. Y., Zhou, Q., Kong, B. H., Huang, Y., Chen, L. P., Li, G. L., An, R. F., Wang, K., … Mirza, M. R. (2021). Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆. Annals of Oncology, 32(4), 512–521. https://doi.org/10.1016/j.annonc.2020.12.018

Wu, X., Liu, J., Wang, J., Wang, L., Lin, Z., Wang, X., Zhu, J., Kong, B., Fei, J., Tang, Y., Xia, B., Liang, Z., Wang, K., Huang, Y., Zheng, H., Lin, A., Jiang, K., Wang, W., Wang, X., … Zeng, L. (2024). Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial. Nature Medicine, 30(6), 1612–1621. https://doi.org/10.1038/s41591-024-03003-9




DOI: https://doi.org/10.33024/mahesa.v5i5.17551

Refbacks

  • Saat ini tidak ada refbacks.


Publisher: Universitas Malahayati Lampung

Creative Commons License
Semua artikel dapat digunakan dibawah lisensi Creative Commons Attribution-ShareAlike 4.0 International License


kostenlose besucherzähler